<DOC>
	<DOCNO>NCT00010361</DOCNO>
	<brief_summary>OBJECTIVES : I . Determine safety total body irradiation fludarabine follow allogeneic peripheral blood stem cell bone marrow transplantation combination cyclosporine mycophenolate mofetil establish mixed chimerism patient inherited disorder . II . Determine whether regimen establish mixed chimerism patient . III . Determine whether mixed chimerism sufficient reverse disease symptoms patient . IV . Determine safety donor lymphocyte infusion eliminate persistent disease patient mixed chimerism .</brief_summary>
	<brief_title>Study Total Body Irradiation Fludarabine Followed By Allogeneic Peripheral Blood Stem Cell Bone Marrow Transplantation Combination With Cyclosporine Mycophenolate Mofetil Patients With Inherited Disorders</brief_title>
	<detailed_description>PROTOCOL OUTLINE : Patients receive fludarabine IV 2 hour day -4 -2 follow total body irradiation peripheral blood stem cell bone marrow transplantation day 0 . Patients also receive oral IV cyclosporine 2-3 time daily day -3 50 ( relate donor ) 100 ( unrelated donor ) oral mycophenolate mofetil twice daily day 0 28 ( relate donor ) 40 ( unrelated donor ) . Patients may also receive donor lymphocyte infusion continue treatment symptom event mixed chimerism absence graft-versus-host disease . Patients follow weekly 1 month , monthly 2 year , annually thereafter .</detailed_description>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Metabolism , Inborn Errors</mesh_term>
	<mesh_term>Granulomatous Disease , Chronic</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Inherited disorder treatable allogeneic peripheral blood bone marrow transplantation At high risk regimen relate toxicity conventional transplant No severe CNS involvement disease , define IQ score le 70 HLA match donor Sibling donor must confirm match HLAA , B , DRB1 Other relate nonrelated donor must match HLAA , B , C , DRB1 , DQB1 A donor homozygous one allele HLAA , B , C , DRB1 , DQB1 allow ( 1 antigen mismatch graftversushost disease , 0 antigen mismatch graftrejection ) Prior/Concurrent Therapy No concurrent growth factor mycophenolate mofetil Patient Characteristics Age : Under 55 Performance status : Not specify Life expectancy : At least 100 day Hematopoietic : Not specify Hepatic : No evidence synthetic dysfunction No severe cirrhosis Renal : Not specify Cardiovascular : LVEF least 30 % No poorly control hypertension multiple antihypertensives Other : No organ dysfunction would preclude survival Not pregnant nursing Fertile patient must use effective contraception 12 month follow study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2006</verification_date>
</DOC>